BioSyent マネジメント

マネジメント基準チェック /34

BioSyentの CEO はRené Goehrumで、 May1999年に任命され、の在任期間は 25.5年です。の年間総報酬はCA$ 747.51Kで、 47.7%給与と52.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の8.61%を直接所有しており、その価値はCA$ 11.28M 。経営陣と取締役会の平均在任期間はそれぞれ6.2年と8.8年です。

主要情報

René Goehrum

最高経営責任者

CA$747.5k

報酬総額

CEO給与比率	47.7%
CEO在任期間	25.5yrs
CEOの所有権	8.6%
経営陣の平均在職期間	6.2yrs
取締役会の平均在任期間	8.8yrs

経営陣の近況

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Dec 02

Recent updates

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

Apr 14

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 19

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

Mar 17

BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Feb 18

Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

Jan 28

BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

Jan 07

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 17

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Dec 02

CEO報酬分析

BioSyent の収益と比較して、René Goehrum の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	CA$7m
Jun 30 2024	n/a	n/a	CA$7m
Mar 31 2024	n/a	n/a	CA$7m
Dec 31 2023	CA$748k	CA$357k	CA$6m
Sep 30 2023	n/a	n/a	CA$6m
Jun 30 2023	n/a	n/a	CA$5m
Mar 31 2023	n/a	n/a	CA$5m
Dec 31 2022	CA$681k	CA$343k	CA$5m
Sep 30 2022	n/a	n/a	CA$6m
Jun 30 2022	n/a	n/a	CA$6m
Mar 31 2022	n/a	n/a	CA$6m
Dec 31 2021	CA$681k	CA$329k	CA$6m
Sep 30 2021	n/a	n/a	CA$5m
Jun 30 2021	n/a	n/a	CA$4m
Mar 31 2021	n/a	n/a	CA$4m
Dec 31 2020	CA$649k	CA$325k	CA$4m
Sep 30 2020	n/a	n/a	CA$4m
Jun 30 2020	n/a	n/a	CA$5m
Mar 31 2020	n/a	n/a	CA$5m
Dec 31 2019	CA$497k	CA$310k	CA$4m
Sep 30 2019	n/a	n/a	CA$5m
Jun 30 2019	n/a	n/a	CA$5m
Mar 31 2019	n/a	n/a	CA$6m
Dec 31 2018	CA$528k	CA$300k	CA$6m
Sep 30 2018	n/a	n/a	CA$5m
Jun 30 2018	n/a	n/a	CA$6m
Mar 31 2018	n/a	n/a	CA$5m
Dec 31 2017	CA$509k	CA$280k	CA$5m

報酬と市場: Renéの総報酬 ($USD 535.15K ) は、 Canadian市場 ($USD 169.37K ) の同規模の企業の平均を上回っています。

報酬と収益: Renéの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

René Goehrum (65 yo)

25.5yrs

在職期間

CA$747,509

報酬

Mr. René C. Goehrum has been the Chairman of BioSyent Inc. since June 1999 and its Chief Executive Officer since May 1999 and also its President since June 2006. Mr. Goehrum served as the President and ser...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
René Goehrum	Chairman	25.5yrs	CA$747.51k	8.61% CA$ 11.3m
Robert March	VP of Finance & CFO	6.2yrs	CA$340.38k	0.49% CA$ 635.7k
Joost van der Mark	Vice President of Corporate Development	6.2yrs	CA$315.75k	0.45% CA$ 595.8k
Neelu Atwal	Director of Human Resources	5.8yrs	データなし	0.17% CA$ 228.0k

6.2yrs

平均在職期間

経験豊富な経営陣: RXの経営陣は経験豊富で経験豊富です（平均在職期間は6.2年）。

取締役

名称	ポジション	在職期間	報酬	所有権
René Goehrum	Chairman	28.8yrs	CA$747.51k	8.61% CA$ 11.3m
Joseph Arcuri	Independent Director	6.5yrs	CA$43.04k	0.097% CA$ 127.4k
Larry Andrews	Independent Director	6.8yrs	CA$39.98k	0.084% CA$ 109.4k
Peter Lockhard	Lead Independent Director	22.4yrs	CA$42.25k	1.55% CA$ 2.0m
Sara Elford	Independent Director	6.8yrs	CA$39.00k	0.13% CA$ 171.2k
Stephen Wilton	Independent Director	10.8yrs	CA$39.00k	0.022% CA$ 29.4k

8.8yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: RXの取締役会は経験豊富であると考えられます ( 8.8年の平均在任期間)。

BioSyent マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Insider recently sold CA$55k worth of stock

BioSyent Inc., Annual General Meeting, May 16, 2024

Insufficient new directors

Insufficient new directors

BioSyent Inc., Annual General Meeting, May 26, 2021

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

December 16, 2024 Declares Fourth Quarter 2024 Dividend, Payable on December 16, 2024

BioSyent Inc. to Report Q3, 2024 Results on Nov 20, 2024

BioSyent's (CVE:RX) Dividend Will Be CA$0.045

Second quarter dividend of CA$0.045 announced

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Biosyent Inc Declares Dividend for the Third Quarter of 2024, Payable on September 15, 2024

Insider recently sold CA$55k worth of stock

First quarter dividend of CA$0.045 announced

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024

BioSyent Inc. to Report Q1, 2024 Results on May 16, 2024

BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

BioSyent Inc., Annual General Meeting, May 16, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioSyent Inc. to Report Q4, 2023 Results on Mar 13, 2024

Upcoming dividend of CA$0.045 per share

BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

Third quarter dividend increased to CA$0.045

BioSyent Inc. Declares First Quarter 2024 Dividend, Payable on March 15, 2024

Upcoming dividend of CA$0.04 per share at 1.9% yield

Price target increased by 13% to CA$9.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

BioSyent Inc. Declares Fourth Quarter 2023 Dividend, Payable on December 15, 2023

BioSyent Inc. to Report Q3, 2023 Results on Nov 16, 2023

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioSyent Inc. Declares Third Quarter 2023 Dividend, Payable on September 15, 2023

BioSyent Inc. to Report Q2, 2023 Results on Aug 22, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

BioSyent Inc. Declares Second Quarter 2023 Dividend, Payable on June 15, 2023

BioSyent Inc. to Report Q1, 2023 Results on May 26, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Inaugural dividend of CA$0.04 per share

BioSyent Inc. Declares Dividend for the First Quarter 2023, Payable on March 15, 2023

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CA$10.00

Insufficient new directors

BioSyent Inc. to Report Q3, 2022 Results on Nov 16, 2022

Now 21% undervalued after recent price drop

BioSyent Inc. Declares Quarterly Dividend, Payable on December 15, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

BioSyent Inc. Announces Adoption of Dividend Policy

BioSyent Inc. to Report Q2, 2022 Results on Aug 23, 2022

BioSyent Inc. to Report Q1, 2022 Results on May 18, 2022

Price target increased to CA$10.00

Insufficient new directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

BioSyent Inc. to Report Q4, 2021 Results on Mar 09, 2022

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CA$0.14 (vs CA$0.075 in 3Q 2020)

Second quarter 2021 earnings released: EPS CA$0.08 (vs CA$0.056 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CA$0.13 (vs CA$0.11 in 1Q 2020)

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

BioSyent Inc., Annual General Meeting, May 26, 2021

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Full year 2020 earnings released: EPS CA$0.29 (vs CA$0.31 in FY 2019)

Biosyent Inc. Announces Combogesic Availability in Many Pharmacies Across Canada

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

BioSyent Inc. to Report Q4, 2020 Results on Mar 17, 2021

BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: CA$8.19

Investor sentiment improved over the past week

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Revenue and earnings miss expectations

BioSyent Inc. to Report Q3, 2020 Results on Nov 26, 2020

マネジメント基準チェック /34